To study how Ripasudil can help for graft survival after corneal transplant

A prospective comparative study to evaluate the effect of different Rho kinase inhibitors as a co adjuvant for endothelial cell survival in post Penetrating Keratoplasty patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/069429

Enrollment

Registered

2024-06-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H179- Unspecified corneal scar and opacity

Interventions

Intervention1: Ripasudil eye drops: Topical Ripasudil drops- 3 drops/day, from first post operative day, for a duration of 6 months Control Intervention1: Predmet, vigamox, cyclomune eye drops: Topica

Eligibility

Inclusion criteria

Inclusion criteria: All patients who will undergo Penetrating Keratoplasty at Sankara Eye Hospital, Bangalore

Exclusion criteria

Exclusion criteria: 1. Re-grafts 2. High risk grafts- Viral keratitis, Highly vascularized grafts 3. Pregnant women, Lactating mothers 4. Any posterior segment diseases 5. one eyed patients

Design outcomes

Primary

Measure	Time frame
To compare the graft clarity between the patients treated with Ripasudil & the control group during immediate postoperative periodTimepoint: 7 to 10 days postoperatively	—

Secondary

Measure	Time frame
To analyze the effect of a Rho Kinase Inhibitor (Ripasudil) on endothelial cell functioning in post Penetrating keratoplasty patients using Specular microscopy & PachymetryTimepoint: 1 month, 3 months & 6 months postoperatively	—

Countries

India

Contacts

Public ContactDr. Malvika Gokhale

Sankara Eye Hospital

drpallavijoshi@gmail.com9819147850

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026